Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AC Immune SA - Common Stock (NQ: ACIU )

2.290 -0.010 (-0.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 142,200
Open 2.330
Bid (Size) 2.250 (1)
Ask (Size) 2.360 (6)
Prev. Close 2.300
Today's Range 2.270 - 2.358
52wk Range 2.190 - 4.978
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune to Participate in Upcoming Investor Conferences
From AC Immune SA
Via GlobeNewswire

Performance

YTD
-19.65%
-19.65%
1 Month
-14.55%
-14.55%
3 Month
-21.58%
-21.58%
6 Month
-29.97%
-29.97%
1 Year
-34.57%
-34.57%

More News

Read More
Eliminating Some Screened Stocks
Via Talk Markets
Topics Stocks / Equities
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
From AC Immune SA
Via GlobeNewswire
S&P 500 Moves Lower; US Crude Oil Inventories Increase
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
Via Benzinga
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday
Via Benzinga
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
From AC Immune SA
Via GlobeNewswire
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
From AC Immune SA
Via GlobeNewswire
RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
Via Benzinga
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
From AC Immune SA
Via GlobeNewswire
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
Via Benzinga
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024
Via InvestorPlace
Gold Down Over 1%; AC Immune Shares Spike Higher
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.